Sichuan Huiyu Pharmaceutical Co. Ltd. Class A

As of June 30, 2026, Sichuan Huiyu Pharmaceutical Co. Ltd. Class A carries a market capitalization of 6.65B, placing it among publicly traded companies globally. Its enterprise value stands at 4.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sichuan Huiyu Pharmaceutical Co. Ltd. Class A's next confirmed earnings release is scheduled for October 31, 2026.

As of June 30, 2026, Sichuan Huiyu Pharmaceutical Co. Ltd. Class A has 625.90M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Sichuan Huiyu Pharmaceutical Co. Ltd. Class A maintains a current ratio of 2.43, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sichuan Huiyu Pharmaceutical Co. Ltd. Class A recorded an income tax benefit of -20.29M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, Sichuan Huiyu Pharmaceutical Co. Ltd. Class A's stock has declined approximately 27.79% over the past 52 weeks. The 50-day moving average sits at 11.70, while the 200-day moving average is 12.31.

As of June 30, 2026, Sichuan Huiyu Pharmaceutical Co. Ltd. Class A holds 2.78B in cash and equivalents against 707.19M in total debt, resulting in a net debt position of -1.83B. Total book value stands at 3.73B, with working capital of 1.99B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sichuan Huiyu Pharmaceutical Co. Ltd. Class A paid dividends of 0.15 per share.

Sichuan Huiyu Pharmaceutical Co. Ltd. Class A's most recent stock split took place on June 17, 2026 with a 25:37 split ratio.